RxDoctor Payments Data

Welborn McClatchey, MD

Internal Medicine · Atlanta, GANPI 1437244704

Payments from drug & device makers

$2,523in general payments, 2019–2025

Across 124 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$376
  • Johnson & Johnson$267
  • Pfizer$261
  • Novo Nordisk$240
  • Abbott$196
  • Lilly USA, LLC$162
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,523 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$468,799
Medicare patients
489
Services billed
9,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$125,024
OzempicSemaglutide70$91,982
MounjaroTirzepatide64$70,062
FarxigaDapagliflozin Propanediol39$47,162
JardianceEmpagliflozin25$28,421
JanuviaSitagliptin Phosphate24$22,477
XareltoRivaroxaban21$21,391
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$10,371
Tresiba Flextouch U-200Insulin Degludec11$7,701
Tresiba Flextouch U-100Insulin Degludec16$6,623
Atorvastatin Calcium742$6,216
PremarinEstrogens, Conjugated16$4,818
Pravastatin Sodium386$4,788
Arnuity ElliptaFluticasone Furoate13$4,262
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$261$129,842129 claims
Novo NordiskOzempic$240$91,98270 claims
Lilly USA, LLCMounjaro$162$70,06264 claims
Boehringer IngelheimJardiance$40$28,42125 claims
MerckJanuvia$44$22,47724 claims
Johnson & JohnsonXarelto$267$21,39121 claims
GSKArnuity Ellipta$106$4,26213 claims
AbbVieSynthroid$62$2,53346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →